Shares of AstraZeneca (AZN) rose 1% on Tuesday morning after it announced that its Calquence (acalabrutinib) in combination with bendamustine and rituximab has been approved in the European Union for ...

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton ...

AstraZeneca (AZ) has announced that its Bruton’s tyrosine kinase (BTK) inhibitor Calquence (acalabrutinib) has been approved by the European Commission (EC) as part of a combination treatment for ...

The FDA is to give AstraZeneca’s cancer drug acalabrutinib a fast review in a rare blood cancer, as the company hopes to shake off disappointing results from a crucial lung cancer trial last week.

Calquence (acalabrutinib) plus bendamustine and rituximab reduced risk for disease progression or death by 27% compared with ...

Cambridge: AstraZeneca has announced that Calquence (acalabrutinib) in combination with bendamustine and rituximab has been ...

AstraZeneca (AZ) has confirmed it is in a ... Acerta has no drugs on the market yet, but its lead candidate acalabrutinib (ACP-196) is a second-generation, irreversible inhibitor of Bruton's ...

The addition of statin medications to contemporary therapies like ibrutinib could significantly improve survival for patients ...

AstraZeneca’s Calquence plus chemoimmunotherapy approved in EU to treat adult patients with previously untreated mantle cell lymphoma: Cambridge, UK Wednesday, May 7, 2025, 09:0 ...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been recommended for approval in the European Union (EU) for the ...